Actimab-A (lintuzumab-Ac-225)

About Actinium Pharmaceuticals

Actinium Pharmaceuticals is a clinical-stage biotech company focused on developing targeted radiotherapies using its proprietary Actinium-225 (Ac-225) technology platform. Its mission is to deliver potent, precise radiation directly to cancer cells, with a pipeline spanning targeted conditioning for bone marrow transplant (Iomab-B), therapies for hematologic cancers (Actimab-A), and a multi-indication solid tumor candidate (ATNM-400). The company's strategy leverages its deep intellectual property in Ac-225 manufacturing and conjugation to create first-in-class therapies, funded through equity offerings and strategic partnerships like its $35M upfront deal with Immedica for Iomab-B.

Therapeutic Areas

Other Relapsed/Refractory AML Drugs